S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
5 Hypergrowth Stocks to Buy Now (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
5 Hypergrowth Stocks to Buy Now (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
5 Hypergrowth Stocks to Buy Now (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
TSE:REUN

Reunion Neuroscience - REUN Stock Forecast, Price & News

C$0.93
-0.05 (-5.10%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
C$0.93
C$1.00
50-Day Range
C$0.93
C$1.84
52-Week Range
C$0.87
C$9.40
Volume
6,509 shs
Average Volume
8,514 shs
Market Capitalization
C$10.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

REUN stock logo

About Reunion Neuroscience (TSE:REUN) Stock

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.

Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

REUN Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
EF Hutton Reaffirms Their Buy Rating on Reunion Neuroscience (REUN)
See More Headlines
Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$-74,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$4.86 million
Book Value
C$2.29 per share

Miscellaneous

Free Float
N/A
Market Cap
C$10.83 million
Optionable
Not Optionable
Beta
4.10

Key Executives

  • Mr. Hannan Fleiman (Age 41)
    Co-Founder & Non-Independent Director
    Comp: $282.64k
  • Mr. Mujeeb Jafferi (Age 38)
    CO-Founder & COO
    Comp: $282.64k
  • Dr. Nathan Bryson B.Sc. (Age 58)
    Ph.D., Chief Scientific Officer
    Comp: $411.37k
  • Mr. Gregory T. Mayes Esq. (Age 53)
    J.D., Pres, CEO & Director
  • Mr. Edward F. Smith CPA (Age 51)
    Chief Financial Officer
  • Mr. Matt Emmer
    Director of Operations & Bus. Devel.
  • Curtis Weber
    Gen. Counsel & Corp. Sec.
  • Mr. Stephan Cote
    Head of Quality
  • Ms. Vicki Reed
    Chief Growth Officer
  • Dr. Michael Verbora M.B.A.
    M.D., Sr. VP & Medical Director













REUN Stock - Frequently Asked Questions

Should I buy or sell Reunion Neuroscience stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reunion Neuroscience in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REUN shares.
View REUN analyst ratings
or view top-rated stocks.

How have REUN shares performed in 2023?

Reunion Neuroscience's stock was trading at C$1.19 at the start of the year. Since then, REUN shares have decreased by 21.8% and is now trading at C$0.93.
View the best growth stocks for 2023 here
.

What is Reunion Neuroscience's stock symbol?

Reunion Neuroscience trades on the Toronto Stock Exchange (TSX) under the ticker symbol "REUN."

How do I buy shares of Reunion Neuroscience?

Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Reunion Neuroscience's stock price today?

One share of REUN stock can currently be purchased for approximately C$0.93.

How much money does Reunion Neuroscience make?

Reunion Neuroscience (TSE:REUN) has a market capitalization of C$10.83 million and generates C$4.86 million in revenue each year. The company earns C$-74,490,000.00 in net income (profit) each year or C($5.67) on an earnings per share basis.

This page (TSE:REUN) was last updated on 4/1/2023 by MarketBeat.com Staff